EFG - ETF AI Analysis
Top Page
iShares MSCI EAFE Growth ETF (EFG)
Rating:65Neutral
Price Target:―
Positive Factors
Global Developed-Market Diversification
The fund spreads its investments across many countries like Japan, the UK, France, the U.S., and others, which helps reduce the impact of problems in any single market.
Growth-Focused Leaders in Key Sectors
Top holdings such as ASML, Novartis, Hitachi, UBS, and Airbus have shown generally solid performance, supporting the ETF’s growth-focused strategy.
Healthy Size and Moderate Costs
With a large asset base and an expense ratio that is reasonable for an international growth fund, the ETF offers scale and access to foreign growth stocks at a moderate ongoing cost.
Negative Factors
Concentration in a Few Countries
A significant portion of the portfolio is invested in a handful of markets like Japan, the UK, France, and Germany, which can increase risk if those economies struggle.
Mixed Performance Among Top Holdings
Some major positions such as AstraZeneca, SAP, LVMH, and Schneider Electric have recently shown weaker performance, which can drag on overall returns.
Sector Tilts May Add Cyclical Risk
Heavy exposure to industrials and technology means the fund may be more sensitive to economic slowdowns and shifts in demand for growth-oriented companies.
EFG vs. SPDR S&P 500 ETF (SPY)
AUM13.57B
RegionDeveloped Markets
Expense Ratio0.36%
Beta0.90
IssueriShares
Inception DateAug 01, 2005
Dividend Yield2.67%
Asset ClassEquity
Index TrackedMSCI EAFE Growth
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,151,973
30 Day Avg. Volume2,379,366
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
135.73Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering362
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EFG Summary
The iShares MSCI EAFE Growth ETF (EFG) invests in fast-growing companies in developed markets outside the U.S. and Canada, following the MSCI EAFE Growth Index. It holds firms from Europe, Japan, and other regions, with a focus on sectors like industrials, technology, and health care. Well-known holdings include ASML Holding and AstraZeneca. Someone might invest in EFG to add international growth stocks to their portfolio and diversify beyond the U.S. market. A key risk is that growth stocks in foreign markets can be volatile and can go up and down with global market conditions.
How much will it cost me?The iShares MSCI EAFE Growth ETF (EFG) has an expense ratio of 0.36%, meaning you’ll pay $3.60 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it tracks a growth-focused index, which requires more active management compared to broad, passively managed funds. It’s still considered reasonable for the specialized exposure it provides.
What would affect this ETF?The iShares MSCI EAFE Growth ETF could benefit from continued innovation and expansion in technology and industrial sectors, which make up a significant portion of its holdings. However, challenges like rising interest rates or economic slowdowns in developed markets outside North America could negatively impact growth-focused companies. Additionally, regulatory changes or geopolitical tensions in regions like Europe or Asia may affect the ETF’s performance.
EFG Top 10 Holdings
EFG leans heavily into non-U.S. growth stories, with Europe and other developed markets doing most of the talking. ASML has been a key engine, rising over the past few months and giving the fund a strong semiconductor and tech tilt, while ABB and Commonwealth Bank of Australia have been steady helpers in industrials and financials. On the flip side, SAP and luxury giant LVMH have been losing steam lately, dragging on returns. Big positions in industrials and health care, via names like Novartis and AstraZeneca, keep the fund anchored despite these mixed signals.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 5.42% | $723.28M | €424.77B | 80.89% | 76 Outperform | |
| AstraZeneca | 3.15% | $420.21M | $301.13B | 30.64% | 80 Outperform | |
| Novartis AG | 3.04% | $405.45M | CHF218.74B | 22.46% | 80 Outperform | |
| SAP SE | 1.84% | $245.78M | €171.65B | -40.06% | 66 Neutral | |
| Schneider Electric | 1.56% | $207.52M | €128.16B | 7.07% | 62 Neutral | |
| Hitachi,Ltd. | 1.40% | $186.91M | ¥20.71T | 26.77% | 77 Outperform | |
| LVMH Moet Hennessy Louis Vuitton | 1.40% | $186.19M | €230.48B | -19.06% | 78 Outperform | |
| Commonwealth Bank of Australia | 1.39% | $185.25M | AU$282.07B | 11.79% | 64 Neutral | |
| Siemens Energy | 1.37% | $182.92M | €120.97B | 185.08% | 72 Outperform | |
| ABB Ltd | 1.33% | $176.92M | CHF113.23B | 38.32% | 78 Outperform |
EFG Technical Analysis
Negative
―
Price Trends
117.61
Negative
115.64
Negative
113.10
Negative
Market Momentum
-2.75
Positive
33.27
Neutral
9.99
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EFG, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 113.07, equal to the 50-day MA of 117.61, and equal to the 200-day MA of 113.10, indicating a bearish trend. The MACD of -2.75 indicates Positive momentum. The RSI at 33.27 is Neutral, neither overbought nor oversold. The STOCH value of 9.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EFG.
EFG Peer Comparison
Comparison Results
Performance Comparison
EFG
iShares MSCI EAFE Growth ETF
107.66
10.04
10.28%
IEFA
iShares Core MSCI EAFE ETF
―
―
―
EFA
iShares MSCI EAFE ETF
―
―
―
EFV
iShares MSCI EAFE Value ETF
―
―
―
SCZ
iShares MSCI EAFE Small-Cap ETF
―
―
―
ESGD
iShares ESG Aware MSCI EAFE ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents